The first MCL-1-selective BH3 mimetics have therapeutic potential for chronic lymphocytic leukemia. (April 2016)

• Record Type: Journal Article
• Authors: Besbes, Samaher; Pocard, Marc; Mirshahi, Massoud; Billard, Christian
• Is Part Of: Critical reviews in oncology/hematology. Volume 100(2016)
• Page Start: 32
• Page End: 36
• Publication Date: 2016-04
• Subjects: BH3 mimetics -- MCL-1 inhibitors -- Apoptosis -- CLL -- Therapy; Oncology -- Periodicals; Hematology -- Periodicals; 616.994
• DOI: 10.1016/j.critrevonc.2016.02.003
• Languages: English
• ISSNs: 1040-8428

Abstract

Abstract: Small-molecule BH3 mimetics are designed to mimic the BH3 domain of BH3-only BCL-2 family members which are antagonists of the prosurvival members (such as BCL-2, BCL-XL and MCL-1). The BH3 mimetics are intended to bind with high affinity to prosurvival proteins, in order to inhibit their functional activity and hence to induce apoptosis in cancer cells. Both navitoclax (BCL-2/BCL-XL antagonist) and ABT-199/venetoclax (BCL- 2-selective inhibitor) have demonstrated therapeutic efficacy especially in chronic lymphocytic leukemia (CLL). However, these BH3 mimetics cannot antagonize the prosurvival protein MCL-1 that is overexpressed and involved in therapeutic resistance in CLL. Furthermore, until now, none of the reported small-molecule MCL-1 inhibitors bound to their target with high affinity. The first MCL- 1-selective BH3 mimetics capable of high-affinity binding and inducing apoptosis in cancer cells through an on-target mechanism have just been identified. This discovery should advance the translational research to implement novel drugs in treating CLL.